OFFICIAL

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED CENTRAL FAX CENTER

APR 1 3 2004

APPLICANT

ROSAZZA, et al.

SERIAL NO

09/225,426

FILED TITLE January 5, 1999
PURIFIED NITRIC OXIDE SYNTHASE

Grp./A.U.

1651

Examiner

Saucier, Sandra E.

Conf. No.

2480

Docket No.

P00297US1

AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Office Action dated March 10, 2004, please amend the above-identified application as follows:

CERTIFICATE OF MAILING/TRANSMISSION (37 CFR 1.8(a))

I hereby certify that this correspondence is, on the date shown below, being:

MAILING

☐ deposited with the United States Postal Service with sufficient postage as First Class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313-1450.

Date: April 13, 2004

FACSIMILE

Itransmitted by facsimile to the Patent and Trademark Office, Art Unit 1651 at Fax No. (703) 872-9306.

Mung

PAGE 2/10 * RCVD AT 4/13/2004 3:50:21 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/3 * DNIS:8729306 * CSID:5152881338 * DURATION (mm-ss):02-52

04/19/2004 TSUBBS 00000002 Z60084

10000

does not recite the use of bradykinin, claim 26 is not anticipated by the '261 patent. Since the '261 patent does not teach or suggest the use of Applicants' other claimed compounds, claim 26 is also not rendered obvious by the '261 patent.

V. Claim Rejections - 35 U.S.C. § 103

Claims 1, 17, and 19 were rejected under 35 U.S.C. 103(a) as being unpatentable over Chahine. The Examiner states that Chahine et al. disclose the administration of bradykinin or des-Arg9-bradykinin to ischemic hearts to decrease fibrillation. Claims 1, 17, and 19 have been canceled from the application, thereby rendering the ground of rejection with respect to these claims moot.

New claim 26 is directed to a method of administering a peptide, oligopeptide or protein selected from the group consisting of Poly-Arginine, Des-Arg1-BK, BK fragment 1-7, [Lys1]-BK, Lys-BK, and Ile-Ser-BK for treating diabetes and gastrointestinal disorders. Chahine et al. do not teach or suggest the use of Applicants' claimed compounds, and therefore does not render claim 26 obvious.

VI. Conclusion

For the above reasons, it is believed that the present application is in a condition for allowability. Allowance is respectfully requested.

Please consider this a one-month extension of time and charge Deposit Account No. 26-0084 for the amount of \$55.00. No other fees or extensions of time are believed to be due in connection with this amendment; however, consider this a request for any fees inadvertently omitted, and charge any additional fees to Deposit Account No. 26-0084.

Respectfully submitted,

WENDY K. MARSH, Reg. No. 39,705 McKER, VOORHEES & SEASE, P.L.C.

801 Grand Avenue, Suite 3200 Des Moines, Iowa 50309-2721

Phone No. (515) 288-3667 Fax No. (515) 288-1338 CUSTOMER NO: 22885

Attorneys of Record

- wm -